Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q3 2020 · 10-Q
Revenue—
Net Income-$18.03M-$18.03MN/M vs Q3 2019 EPS Diluted-$0.29-$0.29N/M vs Q3 2019 Operating Income-$18,123,000N/M Operating Cash Flowderived-$17,536,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,102,000N/M ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end